Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This phase Ib trial studies the side effects and best dose of alemtuzumab when given together
with itacitinib in treating patients with T-cell prolymphocytic leukemia. Itacitinib may stop
the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Immunotherapy with alemtuzumab, may induce changes in body's immune system and may interfere
with the ability of tumor cells to grow and spread. Giving itacitinib and alemtuzumab may
work better in treating patients with T-cell prolymphocytic leukemia compared to standard of
care treatment.